Gilead Sciences Inc. (GILD) Stake Raised by Simmons Bank
Simmons Bank raised its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 2.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,855 shares of the biopharmaceutical company’s stock after buying an additional 650 shares during the period. Simmons Bank’s holdings in Gilead Sciences were worth $1,887,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. BNP Paribas Arbitrage SA increased its position in Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock valued at $181,075,000 after buying an additional 8,430 shares in the last quarter. Evercore Wealth Management LLC increased its position in Gilead Sciences by 1.0% in the second quarter. Evercore Wealth Management LLC now owns 457,553 shares of the biopharmaceutical company’s stock valued at $38,169,000 after buying an additional 4,467 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Gilead Sciences by 6.6% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 444,773 shares of the biopharmaceutical company’s stock valued at $37,103,000 after buying an additional 27,717 shares in the last quarter. Ngam Advisors L.P. increased its position in Gilead Sciences by 9.6% in the second quarter. Ngam Advisors L.P. now owns 169,428 shares of the biopharmaceutical company’s stock valued at $14,134,000 after buying an additional 14,813 shares in the last quarter. Finally, Dearborn Partners LLC increased its position in Gilead Sciences by 8.6% in the second quarter. Dearborn Partners LLC now owns 198,661 shares of the biopharmaceutical company’s stock valued at $16,572,000 after buying an additional 15,761 shares in the last quarter. Institutional investors and hedge funds own 73.59% of the company’s stock.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.19% during trading on Monday, hitting $74.54. The stock had a trading volume of 9,338,882 shares. The company has a market cap of $98.20 billion, a PE ratio of 6.89 and a beta of 1.25. The stock has a 50 day moving average of $74.54 and a 200 day moving average of $80.07. Gilead Sciences Inc. has a 12 month low of $71.39 and a 12 month high of $107.38.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.87 by $0.12. The firm earned $7.40 billion during the quarter, compared to the consensus estimate of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The company’s revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.22 earnings per share. Equities analysts forecast that Gilead Sciences Inc. will post $11.47 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 annualized dividend and a yield of 2.53%. Gilead Sciences’s dividend payout ratio is presently 17.44%.
Several equities analysts have commented on GILD shares. Jefferies Group increased their target price on Gilead Sciences from $91.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, October 5th. Piper Jaffray Cos. reissued a “buy” rating and issued a $108.00 price target on shares of Gilead Sciences in a research note on Monday, August 15th. Berenberg Bank assumed coverage on Gilead Sciences in a research note on Thursday, September 22nd. They issued a “buy” rating for the company. Stifel Nicolaus assumed coverage on Gilead Sciences in a research note on Monday, November 14th. They issued a “buy” rating and a $100.00 price target for the company. They noted that the move was a valuation call. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 6th. Ten analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $97.90.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the sale, the executive vice president now directly owns 132,964 shares in the company, valued at approximately $10,881,773.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John W. Madigan sold 105,000 shares of the business’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the sale, the director now owns 121,761 shares in the company, valued at $9,115,028.46. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.